Balanced news tone
News Sentiment
2171 sentiment intelligence
CARsgen Therapeutics Holdings Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-2.5% over one week, +3.1% over four weeks, trend inactive, and materially above fair value.
Mineralys Therapeutics CMO Rodman sells $65,781 in stock
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Mineralys Therapeutics CMO Rodman sells $65,781 in stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 23:40
- Source
- Investing.com
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 23:15
- Source
- Stock Titan
CARsgen Therapeutics Holdings Limited (stock code: 2171.HK) repurchased 270,000 shares on July 7 at a total cost of HK$4.0603 million.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 14:13
- Source
- Moomoo
CARsgen Therapeutics (SEHK:2171) Is Up 20.8% After First Solid Tumor CAR T Approval - What's Changed
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 03 Jul 2026 07:00
- Source
- simplywall.st
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced?
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 20:32
- Source
- simplywall.st
Hong Kong Stock Market Update | CARsgen Therapeutics-B (02171) Rises Over 3% in Afternoon Trading; Plans to Repurchase Up to 5% of Shares
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 25 Jun 2026 07:00
- Source
- Moomoo
CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jun 2026 07:00
- Source
- PR Newswire
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jun 2026 07:00
- Source
- BioSpace
Multiple affiliate sales and option exercises at Mineralys Therapeutics (MLYS)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- Stock Titan
Carsgen’s zevor-cel CAR T shows long-term survival in MM
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Sep 2025 07:00
- Source
- BioWorld News
CARsgen Therapeutics Announces 2025 Interim Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Aug 2025 07:00
- Source
- PR Newswire
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2025 07:00
- Source
- PR Newswire
CARsgen touts phase 2 stomach cancer win for cell therapy, revs up for China submission
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jan 2025 08:00
- Source
- Fierce Biotech
FDA Removes Clinical Holds Previously Placed on 3 of CARsgen's Oncology Cell Therapies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Nov 2024 08:00
- Source
- CGTLive®
CARsgen Therapeutics officially listing on HKEX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2021 07:00
- Source
- BioPharma APAC